Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E-mutant and SOX2 amplification : Anti-Cancer Drugs

Journal Logo

Case Reports

Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E-mutant and SOX2 amplification

Cerretti, Giuliaa,b,*; Cecchin, Diegoc,*; Denaro, Lucad; Caccese, Marioa,e; Padovan, Martaa,e; Zagonel, Vittorinaa; Lombardi, Giuseppea

Author Information
Anti-Cancer Drugs 34(1):p 190-193, January 2023. | DOI: 10.1097/CAD.0000000000001376

Abstract

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid